https://www.mynewsdesk.com/se/takeda Mynewsdesk RSS - pressmeddelanden, nyheter och blogginlägg. https://www.mynewsdesk.com/se/takeda https://www.mynewsdesk.com/assets/graphics/logos/logo-small-9892f98564f91864075bd14001f8470f2f9bf254729c37044b4b1ac9b0db6b40.png 128 23 sv 15 Thu, 22 Jan 2026 09:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/zasocitinib-tak-279-meets-primary-and-secondary-endpoints-in-phase-3-plaque-psoriasis-studies-3427365?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/zasocitinib-tak-279-meets-primary-and-secondary-endpoints-in-phase-3-plaque-psoriasis-studies-3427365?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 24 Jun 2025 08:00:00 +0200 https://www.mynewsdesk.com/se/takeda/pressreleases/den-foersta-enzymersaettningsterapin-adzynma-rekombinant-adamts13-foer-cttp-nu-tillgaenglig-i-sverige-3393580?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/den-foersta-enzymersaettningsterapin-adzynma-rekombinant-adamts13-foer-cttp-nu-tillgaenglig-i-sverige-3393580?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Fri, 11 Apr 2025 11:49:27 +0200 https://www.mynewsdesk.com/se/takeda/pressreleases/adhd-i-vardagen-en-ny-podd-som-vill-goera-tillvaron-lite-laettare-3380687?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/adhd-i-vardagen-en-ny-podd-som-vill-goera-tillvaron-lite-laettare-3380687?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Fri, 14 Mar 2025 09:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/ny-adhd-app-ska-underlaetta-foer-personer-som-lever-med-adhd-3374705?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/ny-adhd-app-ska-underlaetta-foer-personer-som-lever-med-adhd-3374705?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 04 Mar 2025 14:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/roland-kurney-ny-vd-foer-takeda-sverige-3373316?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/roland-kurney-ny-vd-foer-takeda-sverige-3373316?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Mon, 30 Sep 2024 12:30:50 +0200 https://www.mynewsdesk.com/se/takeda/pressreleases/stor-satsning-paa-precisionsmedicin-foer-inflammatorisk-tarmsjukdom-3345814?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/stor-satsning-paa-precisionsmedicin-foer-inflammatorisk-tarmsjukdom-3345814?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 29 Feb 2024 09:51:39 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/stor-kunskapssatsning-inom-saellsynta-diagnoser-ovanligt-punkt-se-unik-och-ambitioes-plattform-bidrar-till-personcentrerad-vaard-3307114?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/stor-kunskapssatsning-inom-saellsynta-diagnoser-ovanligt-punkt-se-unik-och-ambitioes-plattform-bidrar-till-personcentrerad-vaard-3307114?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 29 Feb 2024 09:43:03 +0100 Det är lätt att det som är ovanligt hamnar i skymundan och därför lanseras nu www.ovanligt.se, en unik storsatsning som fullmatad med innehåll och en unik design blir en digital samlingsplats för ovanliga och sällsynta hälsotillstånd. Förhoppningen är att göra skillnad för de upp till 500 000 svenskar som lever med sällsynta diagnoser, deras nära och kära, patientorganisationer och vården. https://www.mynewsdesk.com/se/takeda/pressreleases/ovanligt-punkt-se-ny-unik-storsatsning-ska-synliggoera-saellsynta-diagnoser-3307109?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/ovanligt-punkt-se-ny-unik-storsatsning-ska-synliggoera-saellsynta-diagnoser-3307109?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Fri, 02 Feb 2024 08:30:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/takedas-hyqvia-godkaend-av-europeiska-kommissionen-som-underhaallsbehandling-vid-kronisk-inflammatorisk-demyeliniserande-polyneuropati-cidp-efter-initiering-med-intravenoesa-immunoglobuliner-3301295?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/takedas-hyqvia-godkaend-av-europeiska-kommissionen-som-underhaallsbehandling-vid-kronisk-inflammatorisk-demyeliniserande-polyneuropati-cidp-efter-initiering-med-intravenoesa-immunoglobuliner-3301295?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 01 Feb 2024 08:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/premiaer-foer-saesong-tvaa-av-saellsynta-podden-3300657?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/premiaer-foer-saesong-tvaa-av-saellsynta-podden-3300657?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Mon, 04 Dec 2023 09:17:48 +0100 En svensk studie, Time after time, visar att kvinnor i genomsnitt diagnostiseras fyra år senare än män. Studien visar även på ökad samsjuklighet hos flickor och kvinnor där förekomsten av ångest och ätstörningar är starkt framträdande. Forskarna hoppas att studien belyser de komplexa utmaningar flickor och kvinnor med adhd möter och kan bidra till att minska ojämlikheter mellan kvinnor och män. https://www.mynewsdesk.com/se/takeda/pressreleases/ny-svensk-studie-bekraeftar-ojaemlikheter-vid-diagnos-av-adhd-kvinnor-faar-adhd-diagnos-flera-aar-senare-aen-maen-kan-leda-till-oekad-psykisk-ohaelsa-3290582?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/ny-svensk-studie-bekraeftar-ojaemlikheter-vid-diagnos-av-adhd-kvinnor-faar-adhd-diagnos-flera-aar-senare-aen-maen-kan-leda-till-oekad-psykisk-ohaelsa-3290582?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 31 Oct 2023 11:31:03 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/denguefeber-oekar-i-allt-fler-laender-som-aer-populaera-resmaal-foer-svenskar-3283115?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/denguefeber-oekar-i-allt-fler-laender-som-aer-populaera-resmaal-foer-svenskar-3283115?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 28 Mar 2023 09:30:00 +0200 https://www.mynewsdesk.com/se/takeda/pressreleases/takeda-staerker-digitalt-initiativ-och-saetter-fokus-paa-flickor-och-kvinnor-med-adhd-3242572?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/takeda-staerker-digitalt-initiativ-och-saetter-fokus-paa-flickor-och-kvinnor-med-adhd-3242572?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 09 Mar 2023 09:15:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/nordic-rare-disease-summit-samlar-experter-foer-att-diskutera-hur-vaarden-av-patienter-med-saellsynta-haelsotillstaand-kan-foerbaettras-i-stockholm-den-17-april-2023-3238548?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/nordic-rare-disease-summit-samlar-experter-foer-att-diskutera-hur-vaarden-av-patienter-med-saellsynta-haelsotillstaand-kan-foerbaettras-i-stockholm-den-17-april-2023-3238548?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 31 Jan 2023 09:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-tredje-avsnittet-av-den-nya-podcastserien-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-slaepps-idag-3230546?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-tredje-avsnittet-av-den-nya-podcastserien-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-slaepps-idag-3230546?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Mon, 16 Jan 2023 09:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-andra-avsnittet-av-den-nya-podcastserien-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-slaepps-idag-3227437?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-andra-avsnittet-av-den-nya-podcastserien-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-slaepps-idag-3227437?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 15 Dec 2022 14:33:34 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/takedas-qdenga-tetravalent-denguevaccin-levande-foersvagat-godkaent-foer-anvaendning-i-eu-3224018?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/takedas-qdenga-tetravalent-denguevaccin-levande-foersvagat-godkaent-foer-anvaendning-i-eu-3224018?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Wed, 14 Dec 2022 10:00:00 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-ny-podcastserie-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-3223429?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/saellsynta-podden-ny-podcastserie-om-saellsynta-sjukdomar-ur-ett-patient-och-anhoerigperspektiv-3223429?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Tue, 29 Nov 2022 09:18:02 +0100 https://www.mynewsdesk.com/se/takeda/pressreleases/eu-kommissionen-godkaenner-livtencity-maribavir-ett-nytt-behandlingsalternativ-foer-transplanterade-patienter-som-drabbats-av-cmv-infektion-som-aer-svaarbehandlad-med-eller-utan-resistens-mot-dagens-standardbehandling-3220436?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/eu-kommissionen-godkaenner-livtencity-maribavir-ett-nytt-behandlingsalternativ-foer-transplanterade-patienter-som-drabbats-av-cmv-infektion-som-aer-svaarbehandlad-med-eller-utan-resistens-mot-dagens-standardbehandling-3220436?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB Thu, 20 Oct 2022 11:05:54 +0200 Positive Opinion for TAK-003 Based on 4.5 Years of Safety and Efficacy Data from Pivotal Phase 3 Trial of 20,000 Children and Adolescents Across Eight Dengue-Endemic Countries. Marketing Authorization Expected in Coming Months in Europe Followed by Regulatory Approvals in Latin America and Asia. https://www.mynewsdesk.com/se/takeda/pressreleases/takeda-receives-positive-chmp-opinion-recommending-approval-of-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries-3212392?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news https://www.mynewsdesk.com/se/takeda/pressreleases/takeda-receives-positive-chmp-opinion-recommending-approval-of-dengue-vaccine-candidate-in-eu-and-dengue-endemic-countries-3212392?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=current_news Takeda Pharma AB